|
|
|
☒
|
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.
|
☐
|
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
|
|
|
|
Maryland
|
|
33-0091377
|
(State or other jurisdiction of
incorporation or organization)
|
|
(I.R.S. Employer
Identification No.)
|
|
Large Accelerated Filer ☒
|
|
Accelerated Filer ☐
|
Non-accelerated Filer ☐
|
|
Smaller Reporting Company ☐
|
(Do not check if a smaller reporting company)
|
|
|
|
|
Emerging Growth Company ☐
|
|
PART I. FINANCIAL INFORMATION
|
|
|
|
|
|
|
||
|
|
|
|
||
|
|
|
|
||
|
|
|
|
||
|
|
|
|
||
|
|
|
|
||
|
|
|
|
||
|
|
|
|
|
|
|
|
|
|
|
|
|
||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
March 31,
2018 |
|
December 31,
2017 |
||||
ASSETS
|
|
|
|
|
|
||
Real estate:
|
|
|
|
|
|
||
Buildings and improvements
|
$
|
11,532,338
|
|
|
$
|
11,239,732
|
|
Development costs and construction in progress
|
344,948
|
|
|
447,976
|
|
||
Land
|
1,808,210
|
|
|
1,785,865
|
|
||
Accumulated depreciation and amortization
|
(2,826,325
|
)
|
|
(2,741,695
|
)
|
||
Net real estate
|
10,859,171
|
|
|
10,731,878
|
|
||
Net investment in direct financing leases
|
713,463
|
|
|
714,352
|
|
||
Loans receivable, net
|
47,012
|
|
|
313,326
|
|
||
Investments in and advances to unconsolidated joint ventures
|
863,775
|
|
|
800,840
|
|
||
Accounts receivable, net of allowance of $4,516 and $4,425, respectively
|
51,468
|
|
|
40,733
|
|
||
Cash and cash equivalents
|
86,021
|
|
|
55,306
|
|
||
Restricted cash
|
31,947
|
|
|
26,897
|
|
||
Intangible assets, net
|
395,298
|
|
|
410,082
|
|
||
Assets held for sale, net
|
436,155
|
|
|
417,014
|
|
||
Other assets, net
|
583,261
|
|
|
578,033
|
|
||
Total assets
|
$
|
14,067,571
|
|
|
$
|
14,088,461
|
|
LIABILITIES AND EQUITY
|
|
|
|
|
|
||
Bank line of credit
|
$
|
1,092,357
|
|
|
$
|
1,017,076
|
|
Term loan
|
236,878
|
|
|
228,288
|
|
||
Senior unsecured notes
|
6,398,976
|
|
|
6,396,451
|
|
||
Mortgage debt
|
143,524
|
|
|
144,486
|
|
||
Other debt
|
93,856
|
|
|
94,165
|
|
||
Intangible liabilities, net
|
52,576
|
|
|
52,579
|
|
||
Liabilities of assets held for sale, net
|
8,564
|
|
|
14,031
|
|
||
Accounts payable and accrued liabilities
|
391,942
|
|
|
401,738
|
|
||
Deferred revenue
|
167,975
|
|
|
144,709
|
|
||
Total liabilities
|
8,586,648
|
|
|
8,493,523
|
|
||
Commitments and contingencies
|
|
|
|
|
|
||
Common stock, $1.00 par value: 750,000,000 shares authorized; 469,725,220 and 469,435,678 shares issued and outstanding, respectively
|
469,725
|
|
|
469,436
|
|
||
Additional paid-in capital
|
8,183,166
|
|
|
8,226,113
|
|
||
Cumulative dividends in excess of earnings
|
(3,425,293
|
)
|
|
(3,370,520
|
)
|
||
Accumulated other comprehensive income (loss)
|
(21,307
|
)
|
|
(24,024
|
)
|
||
Total stockholders' equity
|
5,206,291
|
|
|
5,301,005
|
|
||
Joint venture partners
|
97,744
|
|
|
117,045
|
|
||
Non-managing member unitholders
|
176,888
|
|
|
176,888
|
|
||
Total noncontrolling interests
|
274,632
|
|
|
293,933
|
|
||
Total equity
|
5,480,923
|
|
|
5,594,938
|
|
||
Total liabilities and equity
|
$
|
14,067,571
|
|
|
$
|
14,088,461
|
|
|
Three Months Ended March 31,
|
||||||
|
2018
|
|
2017
|
||||
Revenues:
|
|
|
|
|
|
||
Rental and related revenues
|
$
|
279,578
|
|
|
$
|
286,218
|
|
Tenant recoveries
|
37,174
|
|
|
33,675
|
|
||
Resident fees and services
|
142,814
|
|
|
140,232
|
|
||
Income from direct financing leases
|
13,266
|
|
|
13,712
|
|
||
Interest income
|
6,365
|
|
|
18,331
|
|
||
Total revenues
|
479,197
|
|
|
492,168
|
|
||
Costs and expenses:
|
|
|
|
|
|
||
Interest expense
|
75,102
|
|
|
86,718
|
|
||
Depreciation and amortization
|
143,250
|
|
|
136,554
|
|
||
Operating
|
172,552
|
|
|
159,081
|
|
||
General and administrative
|
29,175
|
|
|
22,478
|
|
||
Transaction costs
|
2,195
|
|
|
1,057
|
|
||
Total costs and expenses
|
422,274
|
|
|
405,888
|
|
||
Other income (expense):
|
|
|
|
|
|
||
Gain (loss) on sales of real estate, net
|
20,815
|
|
|
317,258
|
|
||
Other income (expense), net
|
(40,407
|
)
|
|
51,208
|
|
||
Total other income (expense), net
|
(19,592
|
)
|
|
368,466
|
|
||
Income (loss) before income taxes and equity income (loss) from unconsolidated joint ventures
|
37,331
|
|
|
454,746
|
|
||
Income tax benefit (expense)
|
5,336
|
|
|
6,162
|
|
||
Equity income (loss) from unconsolidated joint ventures
|
570
|
|
|
3,269
|
|
||
Net income (loss)
|
43,237
|
|
|
464,177
|
|
||
Noncontrolling interests' share in earnings
|
(3,005
|
)
|
|
(3,032
|
)
|
||
Net income (loss) attributable to HCP, Inc.
|
40,232
|
|
|
461,145
|
|
||
Participating securities' share in earnings
|
(391
|
)
|
|
(770
|
)
|
||
Net income (loss) applicable to common shares
|
$
|
39,841
|
|
|
$
|
460,375
|
|
Earnings per common share:
|
|
|
|
||||
Basic
|
$
|
0.08
|
|
|
$
|
0.98
|
|
Diluted
|
$
|
0.08
|
|
|
$
|
0.97
|
|
Weighted average shares outstanding:
|
|
|
|
||||
Basic
|
469,557
|
|
|
468,299
|
|
||
Diluted
|
469,695
|
|
|
475,173
|
|
||
|
|
|
|
||||
Dividends declared per common share
|
$
|
0.37
|
|
|
$
|
0.37
|
|
|
Three Months Ended March 31,
|
||||||
|
2018
|
|
2017
|
||||
Net income (loss)
|
$
|
43,237
|
|
|
$
|
464,177
|
|
|
|
|
|
||||
Other comprehensive income (loss):
|
|
|
|
||||
Change in net unrealized gains (losses) on cash flow hedges:
|
|
|
|
||||
Unrealized gains (losses)
|
(5,164
|
)
|
|
(302
|
)
|
||
Reclassification adjustment realized in net income (loss)
|
125
|
|
|
213
|
|
||
Change in Supplemental Executive Retirement Plan obligation and other
|
104
|
|
|
83
|
|
||
Foreign currency translation adjustment
|
7,652
|
|
|
990
|
|
||
Total other comprehensive income (loss)
|
2,717
|
|
|
984
|
|
||
Total comprehensive income (loss)
|
45,954
|
|
|
465,161
|
|
||
Total comprehensive income (loss) attributable to noncontrolling interests
|
(3,005
|
)
|
|
(3,032
|
)
|
||
Total comprehensive income (loss) attributable to HCP, Inc.
|
$
|
42,949
|
|
|
$
|
462,129
|
|
|
Common Stock
|
|
Additional Paid-In Capital
|
|
Cumulative Dividends In Excess Of Earnings
|
|
Accumulated Other Comprehensive Income (Loss)
|
|
Total Stockholders’ Equity
|
|
Total Noncontrolling Interests
|
|
Total
Equity
|
|||||||||||||||||
|
Shares
|
|
Amount
|
|
|
|
|
|
|
|||||||||||||||||||||
December 31, 2017
|
469,436
|
|
|
$
|
469,436
|
|
|
$
|
8,226,113
|
|
|
$
|
(3,370,520
|
)
|
|
$
|
(24,024
|
)
|
|
$
|
5,301,005
|
|
|
$
|
293,933
|
|
|
$
|
5,594,938
|
|
Impact of adoption of ASU No. 2017-05
(1)
|
—
|
|
|
—
|
|
|
—
|
|
|
79,144
|
|
|
—
|
|
|
79,144
|
|
|
—
|
|
|
79,144
|
|
|||||||
January 1, 2018
|
469,436
|
|
|
$
|
469,436
|
|
|
$
|
8,226,113
|
|
|
$
|
(3,291,376
|
)
|
|
$
|
(24,024
|
)
|
|
$
|
5,380,149
|
|
|
$
|
293,933
|
|
|
$
|
5,674,082
|
|
Net income (loss)
|
—
|
|
|
—
|
|
|
—
|
|
|
40,232
|
|
|
—
|
|
|
40,232
|
|
|
3,005
|
|
|
43,237
|
|
|||||||
Other comprehensive income (loss)
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
2,717
|
|
|
2,717
|
|
|
—
|
|
|
2,717
|
|
|||||||
Issuance of common stock, net
|
382
|
|
|
382
|
|
|
2,392
|
|
|
—
|
|
|
—
|
|
|
2,774
|
|
|
—
|
|
|
2,774
|
|
|||||||
Repurchase of common stock
|
(93
|
)
|
|
(93
|
)
|
|
(2,051
|
)
|
|
—
|
|
|
—
|
|
|
(2,144
|
)
|
|
—
|
|
|
(2,144
|
)
|
|||||||
Amortization of deferred compensation
|
—
|
|
|
—
|
|
|
5,919
|
|
|
—
|
|
|
—
|
|
|
5,919
|
|
|
—
|
|
|
5,919
|
|
|||||||
Common dividends ($0.37 per share)
|
—
|
|
|
—
|
|
|
—
|
|
|
(174,149
|
)
|
|
—
|
|
|
(174,149
|
)
|
|
—
|
|
|
(174,149
|
)
|
|||||||
Distributions to noncontrolling interest
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(5,077
|
)
|
|
(5,077
|
)
|
|||||||
Issuances of noncontrolling interest
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
995
|
|
|
995
|
|
|||||||
Purchase of noncontrolling interest
|
—
|
|
|
—
|
|
|
(49,207
|
)
|
|
—
|
|
|
—
|
|
|
(49,207
|
)
|
|
(18,224
|
)
|
|
(67,431
|
)
|
|||||||
March 31, 2018
|
469,725
|
|
|
$
|
469,725
|
|
|
$
|
8,183,166
|
|
|
$
|
(3,425,293
|
)
|
|
$
|
(21,307
|
)
|
|
$
|
5,206,291
|
|
|
$
|
274,632
|
|
|
$
|
5,480,923
|
|
|
Common Stock
|
|
Additional Paid-In Capital
|
|
Cumulative Dividends In Excess Of Earnings
|
|
Accumulated Other Comprehensive Income (Loss)
|
|
Total Stockholders’ Equity
|
|
Total Noncontrolling Interests
|
|
Total
Equity |
|||||||||||||||||
|
Shares
|
|
Amount
|
|
|
|
|
|
|
|||||||||||||||||||||
January 1, 2017
|
468,081
|
|
|
$
|
468,081
|
|
|
$
|
8,198,890
|
|
|
$
|
(3,089,734
|
)
|
|
$
|
(29,642
|
)
|
|
$
|
5,547,595
|
|
|
$
|
393,713
|
|
|
$
|
5,941,308
|
|
Net income (loss)
|
—
|
|
|
—
|
|
|
—
|
|
|
461,145
|
|
|
—
|
|
|
461,145
|
|
|
3,032
|
|
|
464,177
|
|
|||||||
Other comprehensive income (loss)
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
984
|
|
|
984
|
|
|
—
|
|
|
984
|
|
|||||||
Issuance of common stock, net
|
427
|
|
|
427
|
|
|
3,045
|
|
|
—
|
|
|
—
|
|
|
3,472
|
|
|
—
|
|
|
3,472
|
|
|||||||
Conversion of DownREIT units to common stock
|
54
|
|
|
54
|
|
|
1,494
|
|
|
—
|
|
|
—
|
|
|
1,548
|
|
|
(1,548
|
)
|
|
—
|
|
|||||||
Repurchase of common stock
|
(116
|
)
|
|
(116
|
)
|
|
(3,416
|
)
|
|
—
|
|
|
—
|
|
|
(3,532
|
)
|
|
—
|
|
|
(3,532
|
)
|
|||||||
Amortization of deferred compensation
|
—
|
|
|
—
|
|
|
3,765
|
|
|
—
|
|
|
—
|
|
|
3,765
|
|
|
—
|
|
|
3,765
|
|
|||||||
Common dividends ($0.37 per share)
|
—
|
|
|
—
|
|
|
—
|
|
|
(173,629
|
)
|
|
—
|
|
|
(173,629
|
)
|
|
—
|
|
|
(173,629
|
)
|
|||||||
Distributions to noncontrolling interest
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(5,659
|
)
|
|
(5,659
|
)
|
|||||||
Issuances of noncontrolling interest
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
650
|
|
|
650
|
|
|||||||
Deconsolidation of noncontrolling interest
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(58,061
|
)
|
|
(58,061
|
)
|
|||||||
March 31, 2017
|
468,446
|
|
|
$
|
468,446
|
|
|
$
|
8,203,778
|
|
|
$
|
(2,802,218
|
)
|
|
$
|
(28,658
|
)
|
|
$
|
5,841,348
|
|
|
$
|
332,127
|
|
|
$
|
6,173,475
|
|
(1)
|
On January 1, 2018, the Company adopted Accounting Standards Update (“ASU”) No. 2017-05,
Clarifying the Scope of Asset Derecognition Guidance and Accounting for Partial Sales of Nonfinancial Assets
(“ASU 2017-05”), and recognized the cumulative-effect of adoption to beginning retained earnings. Refer to Note 2 for a detailed impact of adoption.
|
|
Three Months Ended March 31,
|
||||||
|
2018
|
|
2017
|
||||
Cash flows from operating activities:
|
|
|
|
||||
Net income (loss)
|
$
|
43,237
|
|
|
$
|
464,177
|
|
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
|
|
|
|
||||
Depreciation and amortization of real estate, in-place lease and other intangibles:
|
143,250
|
|
|
136,554
|
|
||
Amortization of deferred compensation
|
5,919
|
|
|
3,765
|
|
||
Amortization of deferred financing costs
|
3,336
|
|
|
3,858
|
|
||
Straight-line rents
|
(10,686
|
)
|
|
(5,007
|
)
|
||
Equity loss (income) from unconsolidated joint ventures
|
(570
|
)
|
|
(3,269
|
)
|
||
Distributions of earnings from unconsolidated joint ventures
|
5,336
|
|
|
7,842
|
|
||
Deferred income tax expense (benefit)
|
(2,394
|
)
|
|
(8,130
|
)
|
||
Impairments (recoveries), net
|
(3,298
|
)
|
|
—
|
|
||
Loss (gain) on sales of real estate, net
|
(20,815
|
)
|
|
(317,258
|
)
|
||
Loss (gain) on consolidation, net
|
41,017
|
|
|
—
|
|
||
Loss (gain) on sale of marketable securities
|
—
|
|
|
(50,895
|
)
|
||
Other non-cash items
|
(2,401
|
)
|
|
(660
|
)
|
||
Decrease (increase) in accounts receivable and other assets, net
|
(18,082
|
)
|
|
1,136
|
|
||
Increase (decrease) in accounts payable and accrued liabilities
|
12,315
|
|
|
(38,984
|
)
|
||
Net cash provided by (used in) operating activities
|
196,164
|
|
|
193,129
|
|
||
Cash flows from investing activities:
|
|
|
|
||||
Acquisitions of real estate
|
(22,121
|
)
|
|
—
|
|
||
Development and redevelopment of real estate
|
(113,648
|
)
|
|
(75,166
|
)
|
||
Leasing costs, tenant improvements, and recurring capital expenditures
|
(19,246
|
)
|
|
(22,693
|
)
|
||
Proceeds from sales of real estate, net
|
30,392
|
|
|
1,206,256
|
|
||
Contributions to unconsolidated joint ventures
|
(3,688
|
)
|
|
(8,109
|
)
|
||
Distributions in excess of earnings from unconsolidated joint ventures
|
7,257
|
|
|
870
|
|
||
Proceeds from the RIDEA II transaction, net
|
—
|
|
|
462,241
|
|
||
Proceeds from sales/principal repayments on debt investments and direct financing leases
|
132,429
|
|
|
185,364
|
|
||
Investments in loans receivable, direct financing leases and other
|
(647
|
)
|
|
(15,000
|
)
|
||
Net cash provided by (used in) investing activities
|
10,728
|
|
|
1,733,763
|
|
||
Cash flows from financing activities:
|
|
|
|
||||
Borrowings under bank line of credit, net
|
240,000
|
|
|
(375,812
|
)
|
||
Repayments under bank line of credit
|
(170,000
|
)
|
|
(37,032
|
)
|
||
Repayments and repurchase of debt, excluding bank line of credit
|
(1,172
|
)
|
|
(647,427
|
)
|
||
Issuance of common stock and exercise of options
|
2,774
|
|
|
3,472
|
|
||
Repurchase of common stock
|
(2,144
|
)
|
|
(3,532
|
)
|
||
Dividends paid on common stock
|
(174,149
|
)
|
|
(173,629
|
)
|
||
Issuance of noncontrolling interests
|
995
|
|
|
650
|
|
||
Distributions to and purchase of noncontrolling interests
|
(67,542
|
)
|
|
(5,659
|
)
|
||
Net cash provided by (used in) financing activities
|
(171,238
|
)
|
|
(1,238,969
|
)
|
||
Effect of foreign exchanges on cash, cash equivalents and restricted cash
|
111
|
|
|
7
|
|
||
Net increase (decrease) in cash, cash equivalents and restricted cash
|
35,765
|
|
|
687,930
|
|
||
Cash, cash equivalents and restricted cash, beginning of period
|
82,203
|
|
|
136,990
|
|
||
Cash, cash equivalents and restricted cash, end of period
|
$
|
117,968
|
|
|
$
|
824,920
|
|
•
|
The Company, along with its JV partners and independent SHOP operators, provide certain ancillary services to SHOP residents that are not contemplated in the lease with each resident (i.e., guest meals, concierge services, pharmacy services, etc.). These services are provided and paid for in addition to the standard services included in each resident lease (i.e., room and board, standard meals, etc.). The Company bills residents for ancillary services one month in arrears and recognizes revenue as the services are provided, as the Company has no continuing performance obligation related to those services. The Company records ancillary service revenue within resident fees and services and, under the Revenue ASUs, is required to disclose, on an ongoing basis, ancillary service revenue generated from its RIDEA structures. Included within resident fees and services for the quarters ended March 31, 2018 and 2017 is
$10 million
of ancillary service revenue.
|
•
|
Prior to the adoption of the Revenue ASUs, the Company recognized a gain on sale of real estate using the full accrual method when collectibility of the sales price was reasonably assured, the Company was not obligated to perform additional activities that may be considered significant, the initial investment from the buyer was sufficient and other profit recognition criteria had been satisfied. The Company deferred all or a portion of a gain on sale of real estate if the requirements for gain recognition were not met at the time of sale. Subsequent to adopting the Revenue ASUs on January 1, 2018, the Company began recognizing a gain on sale of real estate upon transferring control of the asset to the purchaser, which is generally satisfied at the time of sale. In conjunction with its adoption of the Revenue ASUs, the Company reassessed its historical partial sale of real estate transactions to determine which transactions, if any, were not completed contracts (i.e., the transaction did not qualify for sale treatment under previous guidance). The Company concluded that it had one such material transaction, its partial sale of RIDEA II in the first quarter of 2017 (which was not a completed sale under historical guidance as of the Company's adoption date due to a minor obligation related to the interest sold). In accordance with the Revenue ASUs, the Company recorded its retained
40%
equity investment at fair value as of the sale date. As a result, the Company recorded an adjustment to equity as of January 1, 2018 (under the modified retrospective transition approach) representing a step-up in the fair value of its equity investment in RIDEA II of
$107 million
(to a carrying value of
$121 million
as of January 1, 2018) and a
$30 million
impairment charge to decrease the carrying value to the expected sales price of the investment (see Note 4).
|
•
|
The Company generally expects that the new guidance will result in certain transactions qualifying as sales of real estate at an earlier date than under historical accounting guidance.
|
|
|
March 31, 2018
|
|||||
|
|
As Reported
|
|
As Would Have Been Reported Prior to Adoption
|
|||
Investments in and advances to unconsolidated joint ventures
|
|
863,775
|
|
|
792,291
|
|
|
Other assets, net
|
|
583,261
|
|
|
586,066
|
|
|
Deferred revenue
|
|
167,975
|
|
|
178,440
|
|
|
Total stockholders' equity
|
|
5,206,291
|
|
|
5,127,147
|
|
•
|
ASU No. 2016-01,
Recognition and Measurement of Financial Assets and Financial Liabilities
(“ASU 2016-01”) and ASU No. 2018-03,
Technical Corrections and Improvements to Financial Instruments - Overall
(“ASU 2018-03”). The core principle of the amendments in ASU 2016-01 and ASU 2018-03 involves the measurement of equity investments (except those accounted for under the equity method of accounting or those that result in consolidation) at fair value and the recognition of changes in fair value of those investments during each reporting period in net income (loss). As a result, ASU 2016-01 and ASU 2018-03 eliminate the cost method of accounting for equity securities that do not have readily determinable fair values. Pursuant to the new guidance, an entity may choose to measure equity investments that do not have readily determinable fair values at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer.
|
•
|
ASU No. 2016-16,
Intra-Entity Transfers of Assets Other Than Inventory
(“ASU 2016-16”). The amendments in ASU 2016-16 require an entity to recognize the income tax consequences of intra-entity transfers of assets other than inventory
|
|
|
Three Months Ended March 31, 2017
|
||||||
|
|
As Reported
|
|
As Previously Reported
|
||||
Net cash provided by (used in) investing activities
|
|
$
|
1,733,763
|
|
|
$
|
1,715,217
|
|
Net increase (decrease) in balance
(1)
|
|
687,930
|
|
|
669,384
|
|
||
Balance - beginning of period
(1)
|
|
136,990
|
|
|
94,730
|
|
||
Balance - end of period
(1)
|
|
824,920
|
|
|
764,114
|
|
(1)
|
Amounts in the As Reported column include cash and cash equivalents and restricted cash as required upon the adoption of the Cash Flow ASUs. Amounts in the As Previously Reported column reflect only cash and cash equivalents.
|
•
|
ASU No. 2017-12,
Targeted Improvements to Accounting for Hedging Activities
(“ASU 2017-12”). ASU 2017-12 is effective for fiscal years, including interim periods within, beginning after December 15, 2018 and early adoption is permitted. The amendments in ASU 2017-12 expand and refine hedge accounting for both nonfinancial and financial risk components and align the recognition and presentation of the effects of the hedging instrument and the hedged item in the financial statements. For cash flow and net investment hedges existing at the date of adoption, a reporting entity must apply the amendments in ASU 2017-12 using the modified retrospective approach by recording a cumulative-effect adjustment to equity as of the beginning of the fiscal year of adoption. The presentation and disclosure amendments in ASU 2017-12 must be applied using a prospective approach.
|
•
|
A security deposit (which increases if specified leverage thresholds are exceeded);
|
•
|
A termination right if certain financial covenants and a net worth test are not satisfied;
|
•
|
Enhanced reporting requirements and related remedies; and
|
•
|
The right to market for sale the CCRC portfolio (as defined below).
|
•
|
The Company has the right to sell, or transition to other operators,
32
triple-net assets. If such sale or transition does not occur within
one
year, the triple-net lease with respect to such assets will convert to a cash flow lease (under which the Company will bear the risks and rewards of operating the assets) with a term of
two
years, provided that the Company has the right to terminate the cash flow lease at any time during the term without penalty;
|
•
|
The Company has provided an aggregate
$5 million
annual reduction in rent on
three
assets, effective January 1, 2018; and
|
•
|
The Company will sell
two
triple-net assets to Brookdale or its affiliates for
$35 million
, both of which were sold in April 2018.
|
•
|
The Company, which owned
90%
of the interests in its RIDEA I and RIDEA III JVs with Brookdale at the time the MTCA was executed, agreed to purchase Brookdale’s
10%
noncontrolling interest in each JV for an aggregate purchase price of
$95 million
. These JVs collectively own and operate
58
independent living, assisted living, memory care and/or skilled nursing facilities (the “RIDEA Facilities”). The Company completed its acquisitions of the RIDEA III noncontrolling interest for
$32 million
in December 2017 and the RIDEA I noncontrolling interest for
$63 million
in March 2018;
|
•
|
The Company has the right to sell, or transition to other managers,
36
of the RIDEA Facilities and terminate related management agreements with an affiliate of Brookdale without penalty. If the related management agreements are not terminated within
one
year, the base management fee (
5%
of gross revenues) increases by
1%
of gross revenues per year over the following
two
years to a maximum of
7%
of gross revenues. As of March 31, 2018, the Company had completed the transition of
eight
SHOP assets;
|
•
|
The Company will sell
four
of the RIDEA Facilities to Brookdale or its affiliates for
$239 million
,
one
of which was sold in January 2018 for
$32 million
. The remaining
three
RIDEA Facilities were sold in April 2018 for
$207 million
;
|
•
|
A Brookdale affiliate continues to manage the remaining
18
RIDEA Facilities pursuant to amended management agreements, which provide for extended terms on select assets, modified performance hurdles for extensions and incentive fees, and modified termination rights (including stricter performance-based termination rights, a staggered right to terminate
seven
agreements over a
10
year period beginning in 2021, and a right to terminate at will upon payment of a termination fee, in lieu of sale-related termination rights) and
two
other existing facilities managed in separate RIDEA structures; and
|
•
|
The Company has the right to sell, to certain permitted transferees, its
49%
ownership interest in JVs that own and operate a portfolio of continuing care retirement communities (the “CCRC Portfolio”) and in which Brookdale owns the other
51%
interest (the “CCRC JV”), subject to certain conditions and a right of first offer in favor of Brookdale. Brookdale will have a corresponding right to sell its
51%
interest in the CCRC JV to certain permitted transferees, subject to certain conditions, a right of first offer and a right to terminate management agreements following such sale of Brookdale’s interest, each in favor of HCP. Following a change in control of Brookdale, the Company will have the right to initiate a sale of the CCRC Portfolio, subject to certain rights of first offer and first refusal in favor of Brookdale.
|
|
March 31,
2018 |
|
December 31,
2017 |
||||
Minimum lease payments receivable
|
$
|
1,049,400
|
|
|
$
|
1,062,452
|
|
Estimated residual value
|
504,457
|
|
|
504,457
|
|
||
Less unearned income
|
(840,394
|
)
|
|
(852,557
|
)
|
||
Net investment in direct financing leases
|
$
|
713,463
|
|
|
$
|
714,352
|
|
Properties subject to direct financing leases
|
29
|
|
|
29
|
|
|
|
Carrying
Amount
|
|
Percentage of
DFL Portfolio
|
|
Internal Ratings
|
||||||||||||
Segment
|
|
|
|
Performing DFLs
|
|
Watch List DFLs
|
|
Workout DFLs
|
||||||||||
Senior housing triple-net
|
|
$
|
628,859
|
|
|
88
|
|
$
|
274,264
|
|
|
$
|
354,595
|
|
|
$
|
—
|
|
Other non-reportable segments
|
|
84,604
|
|
|
12
|
|
84,604
|
|
|
—
|
|
|
—
|
|
||||
|
|
$
|
713,463
|
|
|
100
|
|
$
|
358,868
|
|
|
$
|
354,595
|
|
|
$
|
—
|
|
|
March 31, 2018
|
|
December 31, 2017
|
||||||||||||||||||||
|
Real Estate
Secured
|
|
Other
Secured
|
|
Total
|
|
Real Estate
Secured
|
|
Other
Secured
|
|
Total
|
||||||||||||
Mezzanine
(1)
|
$
|
—
|
|
|
$
|
22,105
|
|
|
$
|
22,105
|
|
|
$
|
—
|
|
|
$
|
269,299
|
|
|
$
|
269,299
|
|
Other
(2)
|
24,990
|
|
|
—
|
|
|
24,990
|
|
|
188,418
|
|
|
—
|
|
|
188,418
|
|
||||||
Unamortized discounts, fees and costs
|
—
|
|
|
(83
|
)
|
|
(83
|
)
|
|
—
|
|
|
(596
|
)
|
|
(596
|
)
|
||||||
Allowance for loan losses
(3)
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(143,795
|
)
|
|
(143,795
|
)
|
||||||
|
$
|
24,990
|
|
|
$
|
22,022
|
|
|
$
|
47,012
|
|
|
$
|
188,418
|
|
|
$
|
124,908
|
|
|
$
|
313,326
|
|
(1)
|
In December 2017, the Company entered into a participating debt financing arrangement to fund a
$115 million
senior living development project, which remained unfunded at
March 31, 2018
.
|
(2)
|
Represents loans denominated in British pound sterling (“GBP”). At
December 31, 2017
, includes the U.K. Bridge Loan discussed below.
|
(3)
|
Related to the Company’s mezzanine loan facility to Tandem Health Care discussed below.
|
|
|
Carrying
Amount
|
|
Percentage of
Loan Portfolio
|
|
Internal Ratings
|
||||||||||||
Investment Type
|
|
|
|
Performing Loans
|
|
Watch List Loans
|
|
Workout Loans
|
||||||||||
Real estate secured
|
|
$
|
24,990
|
|
|
53
|
|
$
|
24,990
|
|
|
$
|
—
|
|
|
$
|
—
|
|
Other secured
|
|
22,022
|
|
|
47
|
|
22,022
|
|
|
—
|
|
|
—
|
|
||||
|
|
$
|
47,012
|
|
|
100
|
|
$
|
47,012
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
|
|
|
|
|
Carrying Amount
|
||||||||
|
|
|
|
|
|
|
|
March 31,
|
|
December 31,
|
||||
Entity
(1)
|
|
|
|
Ownership%
|
|
2018
|
|
2017
|
||||||
CCRC JV
|
|
|
|
|
49
|
|
|
$
|
395,005
|
|
|
$
|
400,241
|
|
RIDEA II
(2)
|
|
|
|
|
40
|
|
|
328,873
|
|
|
259,651
|
|
||
Life Science JVs
(3)
|
|
|
|
|
50 - 63
|
|
|
65,016
|
|
|
65,581
|
|
||
MBK JV
|
|
|
|
|
50
|
|
|
37,442
|
|
|
38,005
|
|
||
Development JVs
(4)
|
|
|
|
|
50 - 90
|
|
|
23,733
|
|
|
23,365
|
|
||
Medical Office JVs
(5)
|
|
|
|
|
20 - 67
|
|
|
12,395
|
|
|
12,488
|
|
||
K&Y JVs
(6)
|
|
|
|
|
80
|
|
|
1,298
|
|
|
1,283
|
|
||
Advances to unconsolidated joint ventures, net
|
|
|
|
|
|
|
|
13
|
|
|
226
|
|
||
|
|
|
|
|
|
|
|
$
|
863,775
|
|
|
$
|
800,840
|
|
(1)
|
These entities are not consolidated because the Company does not control, through voting rights or other means, the JVs.
|
(2)
|
Effective January 1, 2018, the Company increased its carrying value in RIDEA II as a net adjustment to retained earnings under its elected transition approach in accordance with the adoption of ASU 2017-05 (see Note 2). See Note 4 for further information on the deconsolidation and pending sale of RIDEA II.
|
(3)
|
Includes the following unconsolidated partnerships (and the Company’s ownership percentage): (i) Torrey Pines Science Center, LP (
50%
); (ii) Britannia Biotech Gateway, LP (
55%
); and (iii) LASDK, LP (
63%
).
|
(4)
|
Includes
four
unconsolidated SHOP development partnerships (and the Company’s ownership percentage): (i) Vintage Park Development JV (
85%
); (ii) Waldwick JV (
85%
); (iii) Otay Ranch JV (
90%
); and (iv) MBK Development JV (
50%
).
|
(5)
|
Includes
three
unconsolidated medical office partnerships (and the Company’s ownership percentage): HCP Ventures IV, LLC (
20%
); HCP Ventures III, LLC (
30%
); and Suburban Properties, LLC (
67%
).
|
(6)
|
Includes three unconsolidated JVs.
|
Intangible lease assets
|
|
March 31,
2018 |
|
December 31,
2017 |
||||
Gross intangible lease assets
|
|
$
|
732,110
|
|
|
$
|
795,305
|
|
Accumulated depreciation and amortization
|
|
(336,812
|
)
|
|
(385,223
|
)
|
||
Intangible assets, net
|
|
$
|
395,298
|
|
|
$
|
410,082
|
|
Intangible lease liabilities
|
|
March 31,
2018 |
|
December 31,
2017 |
||||
Gross intangible lease liabilities
|
|
$
|
124,609
|
|
|
$
|
126,212
|
|
Accumulated depreciation and amortization
|
|
(72,033
|
)
|
|
(73,633
|
)
|
||
Intangible liabilities, net
|
|
$
|
52,576
|
|
|
$
|
52,579
|
|
Date
|
|
Amount
|
|
Coupon Rate
|
|||
May 1, 2017
|
|
$
|
250,000
|
|
|
5.625
|
%
|
July 27, 2017
|
|
$
|
500,000
|
|
|
5.375
|
%
|
Year
|
|
Bank Line of
Credit
(1)
|
|
Term Loan
(2)
|
|
Senior
Unsecured
Notes
(3)
|
|
Mortgage
Debt
(4)
|
|
Total
(5)
|
||||||||||
2018 (nine months)
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
2,649
|
|
|
$
|
2,649
|
|
2019
|
|
—
|
|
|
237,175
|
|
|
450,000
|
|
|
3,700
|
|
|
690,875
|
|
|||||
2020
|
|
—
|
|
|
—
|
|
|
800,000
|
|
|
3,758
|
|
|
803,758
|
|
|||||
2021
|
|
1,092,357
|
|
|
—
|
|
|
700,000
|
|
|
11,117
|
|
|
1,803,474
|
|
|||||
2022
|
|
—
|
|
|
—
|
|
|
900,000
|
|
|
2,861
|
|
|
902,861
|
|
|||||
Thereafter
|
|
—
|
|
|
—
|
|
|
3,600,000
|
|
|
113,619
|
|
|
3,713,619
|
|
|||||
|
|
1,092,357
|
|
|
237,175
|
|
|
6,450,000
|
|
|
137,704
|
|
|
7,917,236
|
|
|||||
(Discounts), premium and debt costs, net
|
|
—
|
|
|
(297
|
)
|
|
(51,024
|
)
|
|
5,820
|
|
|
(45,501
|
)
|
|||||
|
|
$
|
1,092,357
|
|
|
$
|
236,878
|
|
|
$
|
6,398,976
|
|
|
$
|
143,524
|
|
|
$
|
7,871,735
|
|
(1)
|
Includes
£105 million
translated into U.S. dollars (“USD”).
|
(2)
|
Represents
£169 million
translated into USD.
|
(3)
|
Effective interest rates on the notes ranged from
2.79%
to
6.88%
with a weighted average effective interest rate of
4.20%
and a weighted average maturity of
six years
.
|
(4)
|
Interest rates on the mortgage debt ranged from
1.95%
to
5.91%
with a weighted average effective interest rate of
4.18%
and a weighted average maturity of
20 years
.
|
(5)
|
Excludes
$94 million
of other debt that have no scheduled maturities.
|
|
March 31,
2018 |
|
December 31,
2017 |
||||
Cumulative foreign currency translation adjustment
|
$
|
697
|
|
|
$
|
(6,955
|
)
|
Unrealized gains (losses) on cash flow hedges, net
|
(18,989
|
)
|
|
(13,950
|
)
|
||
Supplemental Executive Retirement plan minimum liability and other
|
(3,015
|
)
|
|
(3,119
|
)
|
||
Total other comprehensive income (loss)
|
$
|
(21,307
|
)
|
|
$
|
(24,024
|
)
|
|
|
Senior Housing Triple-Net
|
|
SHOP
|
|
Life Science
|
|
Medical Office
|
|
Other Non-reportable
|
|
Corporate Non-segment
|
|
Total
|
||||||||||||||
Rental revenues
(1)
|
|
$
|
74,289
|
|
|
$
|
144,670
|
|
|
$
|
99,622
|
|
|
$
|
123,935
|
|
|
$
|
30,316
|
|
|
$
|
—
|
|
|
$
|
472,832
|
|
Operating expenses
|
|
(1,045
|
)
|
|
(101,746
|
)
|
|
(21,809
|
)
|
|
(46,696
|
)
|
|
(1,256
|
)
|
|
—
|
|
|
(172,552
|
)
|
|||||||
NOI
|
|
73,244
|
|
|
42,924
|
|
|
77,813
|
|
|
77,239
|
|
|
29,060
|
|
|
—
|
|
|
300,280
|
|
|||||||
Adjustments to NOI
(2)
|
|
(1,865
|
)
|
|
(1,607
|
)
|
|
(3,751
|
)
|
|
(1,071
|
)
|
|
(1,392
|
)
|
|
—
|
|
|
(9,686
|
)
|
|||||||
Adjusted NOI
|
|
71,379
|
|
|
41,317
|
|
|
74,062
|
|
|
76,168
|
|
|
27,668
|
|
|
—
|
|
|
290,594
|
|
|||||||
Addback adjustments
|
|
1,865
|
|
|
1,607
|
|
|
3,751
|
|
|
1,071
|
|
|
1,392
|
|
|
—
|
|
|
9,686
|
|
|||||||
Interest income
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
6,365
|
|
|
—
|
|
|
6,365
|
|
|||||||
Interest expense
|
|
(600
|
)
|
|
(988
|
)
|
|
(83
|
)
|
|
(120
|
)
|
|
(728
|
)
|
|
(72,583
|
)
|
|
(75,102
|
)
|
|||||||
Depreciation and amortization
|
|
(21,906
|
)
|
|
(27,628
|
)
|
|
(36,080
|
)
|
|
(45,519
|
)
|
|
(12,117
|
)
|
|
—
|
|
|
(143,250
|
)
|
|||||||
General and administrative
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(29,175
|
)
|
|
(29,175
|
)
|
|||||||
Transaction costs
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(2,195
|
)
|
|
(2,195
|
)
|
|||||||
Gain (loss) on sales of real estate, net
|
|
—
|
|
|
20,815
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
20,815
|
|
|||||||
Other income (expense), net
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(40,567
|
)
|
|
160
|
|
|
(40,407
|
)
|
|||||||
Income tax benefit (expense)
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
5,336
|
|
|
5,336
|
|
|||||||
Equity income (loss) from unconsolidated JVs
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
570
|
|
|
—
|
|
|
570
|
|
|||||||
Net income (loss)
|
|
$
|
50,738
|
|
|
$
|
35,123
|
|
|
$
|
41,650
|
|
|
$
|
31,600
|
|
|
$
|
(17,417
|
)
|
|
$
|
(98,457
|
)
|
|
$
|
43,237
|
|
(1)
|
Represents rental and related revenues, tenant recoveries, resident fees and services, and income from DFLs.
|
(2)
|
Represents straight-line rents, DFL non-cash interest, amortization of market lease intangibles, net, deferral of community fees, net and termination fees.
|
|
|
Senior Housing Triple-Net
|
|
SHOP
|
|
Life Science
|
|
Medical Office
|
|
Other Non-reportable
|
|
Corporate Non-segment
|
|
Total
|
||||||||||||||
Rental revenues
(1)
|
|
$
|
100,034
|
|
|
$
|
140,228
|
|
|
$
|
85,321
|
|
|
$
|
118,371
|
|
|
$
|
29,883
|
|
|
$
|
—
|
|
|
$
|
473,837
|
|
Operating expenses
|
|
(1,111
|
)
|
|
(94,539
|
)
|
|
(17,319
|
)
|
|
(44,864
|
)
|
|
(1,248
|
)
|
|
—
|
|
|
(159,081
|
)
|
|||||||
NOI
|
|
98,923
|
|
|
45,689
|
|
|
68,002
|
|
|
73,507
|
|
|
28,635
|
|
|
—
|
|
|
314,756
|
|
|||||||
Adjustments to NOI
(2)
|
|
(1,839
|
)
|
|
(310
|
)
|
|
(305
|
)
|
|
(961
|
)
|
|
(1,012
|
)
|
|
—
|
|
|
(4,427
|
)
|
|||||||
Adjusted NOI
|
|
97,084
|
|
|
45,379
|
|
|
67,697
|
|
|
72,546
|
|
|
27,623
|
|
|
—
|
|
|
310,329
|
|
|||||||
Addback adjustments
|
|
1,839
|
|
|
310
|
|
|
305
|
|
|
961
|
|
|
1,012
|
|
|
—
|
|
|
4,427
|
|
|||||||
Interest income
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
18,331
|
|
|
—
|
|
|
18,331
|
|
|||||||
Interest expense
|
|
(627
|
)
|
|
(4,596
|
)
|
|
(104
|
)
|
|
(129
|
)
|
|
(1,997
|
)
|
|
(79,265
|
)
|
|
(86,718
|
)
|
|||||||
Depreciation and amortization
|
|
(26,411
|
)
|
|
(26,358
|
)
|
|
(33,791
|
)
|
|
(42,729
|
)
|
|
(7,265
|
)
|
|
—
|
|
|
(136,554
|
)
|
|||||||
General and administrative
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(22,478
|
)
|
|
(22,478
|
)
|
|||||||
Transaction costs
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(1,057
|
)
|
|
(1,057
|
)
|
|||||||
Gain (loss) on sales of real estate, net
|
|
268,464
|
|
|
366
|
|
|
44,633
|
|
|
—
|
|
|
3,795
|
|
|
—
|
|
|
317,258
|
|
|||||||
Other income (expense), net
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
50,895
|
|
|
313
|
|
|
51,208
|
|
|||||||
Income tax benefit (expense)
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
6,162
|
|
|
6,162
|
|
|||||||
Equity income (loss) from unconsolidated JVs
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
3,269
|
|
|
—
|
|
|
3,269
|
|
|||||||
Net income (loss)
|
|
$
|
340,349
|
|
|
$
|
15,101
|
|
|
$
|
78,740
|
|
|
$
|
30,649
|
|
|
$
|
95,663
|
|
|
$
|
(96,325
|
)
|
|
$
|
464,177
|
|
(1)
|
Represents rental and related revenues, tenant recoveries, resident fees and services, and income from DFLs.
|
(2)
|
Represents straight-line rents, DFL non-cash interest, amortization of market lease intangibles, net, deferral of community fees, net and termination fees.
|
|
|
Three Months Ended March 31,
|
||||||
Segment
|
|
2018
|
|
2017
|
||||
Senior housing triple-net
|
|
$
|
74,289
|
|
|
$
|
100,034
|
|
SHOP
|
|
144,670
|
|
|
140,228
|
|
||
Life science
|
|
99,622
|
|
|
85,321
|
|
||
Medical office
|
|
123,935
|
|
|
118,371
|
|
||
Other non-reportable segments
|
|
36,681
|
|
|
48,214
|
|
||
Total revenues
|
|
$
|
479,197
|
|
|
$
|
492,168
|
|
|
Three Months Ended
March 31, |
||||||
|
2018
|
|
2017
|
||||
Numerator
|
|
|
|
||||
Net income (loss) from continuing operations
|
$
|
43,237
|
|
|
$
|
464,177
|
|
Noncontrolling interests' share in earnings
|
(3,005
|
)
|
|
(3,032
|
)
|
||
Net income (loss) attributable to HCP, Inc.
|
40,232
|
|
|
461,145
|
|
||
Less: Participating securities' share in earnings
|
(391
|
)
|
|
(770
|
)
|
||
Net income (loss) applicable to common shares
|
$
|
39,841
|
|
|
$
|
460,375
|
|
Numerator - Dilutive
|
|
|
|
|
|
||
Net income (loss) applicable to common shares
|
$
|
39,841
|
|
|
$
|
460,375
|
|
Add: distributions on dilutive convertible units and other
|
—
|
|
|
2,803
|
|
||
Dilutive net income (loss) available to common shares
|
$
|
39,841
|
|
|
$
|
463,178
|
|
Denominator
|
|
|
|
|
|
||
Basic weighted average shares outstanding
|
469,557
|
|
|
468,299
|
|
||
Dilutive potential common shares - equity awards
|
138
|
|
|
229
|
|
||
Dilutive potential common shares - DownREIT conversions
|
—
|
|
|
6,645
|
|
||
Diluted weighted average common shares
|
469,695
|
|
|
475,173
|
|
||
Earnings per common share:
|
|
|
|
||||
Basic
|
$
|
0.08
|
|
|
$
|
0.98
|
|
Diluted
|
$
|
0.08
|
|
|
$
|
0.97
|
|
|
Three Months Ended March 31,
|
||||||
|
2018
|
|
2017
|
||||
Supplemental cash flow information:
|
|
|
|
|
|
||
Interest paid, net of capitalized interest
|
$
|
92,701
|
|
|
$
|
108,232
|
|
Income taxes paid
|
340
|
|
|
1,105
|
|
||
Capitalized interest
|
3,578
|
|
|
3,090
|
|
||
Supplemental schedule of non-cash investing and financing activities:
|
|
|
|
||||
Accrued construction costs
|
62,160
|
|
|
51,498
|
|
||
Derecognition of U.K. Bridge Loan receivable
|
147,474
|
|
|
—
|
|
||
Consolidation of net assets related to U.K. Bridge Loan
|
106,457
|
|
|
—
|
|
||
Deconsolidation of noncontrolling interest in connection with RIDEA II transaction
|
—
|
|
|
58,061
|
|
||
Vesting of restricted stock units and conversion of non-managing member units into common stock
|
258
|
|
|
1,841
|
|
|
|
March 31,
|
||||||
|
|
2018
|
|
2017
|
||||
Cash and cash equivalents
|
|
$
|
86,021
|
|
|
$
|
764,114
|
|
Restricted cash
|
|
31,947
|
|
|
60,806
|
|
||
Cash, cash equivalents and restricted cash
|
|
$
|
117,968
|
|
|
$
|
824,920
|
|
VIE Type
|
|
Asset/Liability Type
|
|
Maximum Loss
Exposure
and Carrying
Amount
(1)
|
||
VIE tenants - DFLs
(2)
|
|
Net investment in DFLs
|
|
$
|
600,822
|
|
VIE tenants - operating leases
(2)
|
|
Lease intangibles, net and straight-line rent receivables
|
|
5,983
|
|
|
CCRC OpCo
|
|
Investments in unconsolidated joint ventures
|
|
190,662
|
|
|
RIDEA II PropCo
|
|
Investments in unconsolidated joint ventures
|
|
309,882
|
|
|
Unconsolidated Development JVs
|
|
Investments in unconsolidated joint ventures
|
|
13,070
|
|
|
Loan - Seller Financing
|
|
Loans receivable, net
|
|
10,000
|
|
|
CMBS and LLC investment
|
|
Marketable debt and cost method investment
|
|
33,874
|
|
(1)
|
The Company’s maximum loss exposure represents the aggregate carrying amount of such investments (including accrued interest).
|
(2)
|
The Company’s maximum loss exposure may be mitigated by re-leasing the underlying properties to new tenants upon an event of default.
|
|
March 31, 2018
|
|
December 31, 2017
|
||||
Assets
|
|
|
|
||||
Buildings and improvements
|
$
|
1,744,402
|
|
|
$
|
2,436,414
|
|
Development costs and construction in progress
|
16,226
|
|
|
32,285
|
|
||
Land
|
170,889
|
|
|
227,162
|
|
||
Accumulated depreciation and amortization
|
(345,331
|
)
|
|
(542,091
|
)
|
||
Net real estate
|
1,586,186
|
|
|
2,153,770
|
|
||
Investments in and advances to unconsolidated joint ventures
|
2,148
|
|
|
2,231
|
|
||
Accounts receivable, net
|
7,287
|
|
|
10,242
|
|
||
Cash and cash equivalents
|
12,077
|
|
|
15,861
|
|
||
Restricted cash
|
2,595
|
|
|
2,619
|
|
||
Intangible assets, net
|
111,149
|
|
|
125,475
|
|
||
Other assets, net
|
35,788
|
|
|
33,749
|
|
||
Total assets
|
$
|
1,757,230
|
|
|
$
|
2,343,947
|
|
Liabilities
|
|
|
|
||||
Mortgage debt
|
44,882
|
|
|
45,016
|
|
||
Intangible liabilities, net
|
12,509
|
|
|
10,672
|
|
||
Accounts payable and accrued liabilities
|
223,708
|
|
|
269,280
|
|
||
Deferred revenue
|
15,275
|
|
|
14,432
|
|
||
Total liabilities
|
$
|
296,374
|
|
|
$
|
339,400
|
|
|
|
Percentage of Total Assets
|
||||||
|
|
Total Company
|
|
Senior Housing Triple-Net
|
||||
|
|
March 31,
|
|
December 31,
|
|
March 31,
|
|
December 31,
|
Tenant
|
|
2018
|
|
2017
|
|
2018
|
|
2017
|
Brookdale
|
|
10
|
|
10
|
|
39
|
|
39
|
|
|
Percentage of Revenues
|
||||||
|
|
Total Company
|
|
Senior Housing Triple-Net
|
||||
|
|
Three Months Ended March 31,
|
|
Three Months Ended March 31,
|
||||
Tenant
|
|
2018
|
|
2017
|
|
2018
|
|
2017
|
Brookdale
(1)
|
|
7
|
|
12
|
|
43
|
|
60
|
(1)
|
The Company's concentration with respect to Brookdale as a tenant is expected to decrease with the completion of the Brookdale Transactions (see Note 3). Includes revenues from
64
senior housing triple-net facilities that were sold in March 2017.
|
|
March 31, 2018
(3)
|
|
December 31, 2017
(3)
|
||||||||||||
|
Carrying
Value
|
|
Fair Value
|
|
Carrying
Value
|
|
Fair Value
|
||||||||
Loans receivable, net
(2)
|
$
|
47,012
|
|
|
$
|
47,075
|
|
|
$
|
313,326
|
|
|
$
|
313,242
|
|
Marketable debt securities
(2)
|
18,814
|
|
|
18,814
|
|
|
18,690
|
|
|
18,690
|
|
||||
Bank line of credit
(2)
|
1,092,357
|
|
|
1,092,357
|
|
|
1,017,076
|
|
|
1,017,076
|
|
||||
Term loan
(2)
|
236,878
|
|
|
236,878
|
|
|
228,288
|
|
|
228,288
|
|
||||
Senior unsecured notes
(1)
|
6,398,976
|
|
|
6,577,155
|
|
|
6,396,451
|
|
|
6,737,825
|
|
||||
Mortgage debt
(2)
|
143,524
|
|
|
137,704
|
|
|
144,486
|
|
|
125,984
|
|
||||
Other debt
(2)
|
93,856
|
|
|
93,856
|
|
|
94,165
|
|
|
94,165
|
|
||||
Interest-rate swap liabilities
(2)
|
1,931
|
|
|
1,931
|
|
|
2,483
|
|
|
2,483
|
|
||||
Cross currency swap liability
(2)
|
16,684
|
|
|
16,684
|
|
|
10,968
|
|
|
10,968
|
|
(1)
|
Level 1: Fair value calculated based on quoted prices in active markets.
|
(2)
|
Level 2: Fair value based on (i) for marketable debt securities, quoted prices for similar or identical instruments in active or inactive markets, respectively, or (ii) for loans receivable, net, mortgage debt, and swaps, calculated utilizing standardized pricing models in which significant inputs or value drivers are observable in active markets. For bank line of credit, term loan and other debt, the carrying values are a reasonable estimate of fair value because the borrowings are primarily based on market interest rates and the Company’s credit rating.
|
(3)
|
During the
three
months ended
March 31, 2018
and year ended
December 31, 2017
, there were no material transfers of financial assets or liabilities within the fair value hierarchy.
|
Date Entered
|
|
Maturity Date
|
|
Hedge Designation
|
|
Notional
|
|
Pay Rate
|
|
Receive Rate
|
|
Fair Value
(1)
|
|||||
Interest rate:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||
July 2005
(2)
|
|
July 2020
|
|
Cash Flow
|
|
$
|
43,000
|
|
|
3.82%
|
|
BMA Swap Index
|
|
|
$
|
(1,931
|
)
|
Cross currency swap:
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||
April 2017
(3)
|
|
February 2019
|
|
Net Investment
|
|
£105,000 / $131,000
|
|
|
2.58%
|
|
3.75
|
%
|
|
$
|
(16,684
|
)
|
(1)
|
Derivative assets are recorded in other assets, net and derivative liabilities are recorded in accounts payable and accrued liabilities on the consolidated balance sheets.
|
(2)
|
Represents
three
interest-rate swap contracts, which hedge fluctuations in interest payments on variable-rate secured debt due to overall changes in hedged cash flows.
|
(3)
|
Represents a cross currency swap to pay
2.58%
on
£105 million
and receive
3.75%
on
$131 million
through February 1, 2019, with an initial and final exchange of principals at origination and maturity at a rate of
1.251
USD/GBP. Hedges the risk of changes in the USD equivalent value of a portion of the Company’s net investment in its consolidated GBP subsidiaries’ attributable to changes in the USD/GBP exchange rate.
|
•
|
our reliance on a concentration of a small number of tenants and operators for a significant percentage of our revenues;
|
•
|
the financial condition of our existing and future tenants, operators and borrowers, including potential bankruptcies and downturns in their businesses, and their legal and regulatory proceedings, which results in uncertainties regarding our ability to continue to realize the full benefit of such tenants’ and operators’ leases and borrowers’ loans;
|
•
|
the ability of our existing and future tenants, operators and borrowers to conduct their respective businesses in a manner sufficient to maintain or increase their revenues and to generate sufficient income to make rent and loan payments to us and our ability to recover investments made, if applicable, in their operations;
|
•
|
competition for the acquisition and financing of suitable healthcare properties as well as competition for tenants and operators, including with respect to new leases and mortgages and the renewal or rollover of existing leases;
|
•
|
our concentration in the healthcare property sector, particularly in senior housing, life sciences and medical office buildings, which makes our profitability more vulnerable to a downturn in a specific sector than if we were investing in multiple industries;
|
•
|
our ability to identify replacement tenants and operators and the potential renovation costs and regulatory approvals associated therewith;
|
•
|
the risks associated with property development and redevelopment, including costs above original estimates, project delays and lower occupancy rates and rents than expected;
|
•
|
the risks associated with our investments in joint ventures and unconsolidated entities, including our lack of sole decision making authority and our reliance on our partners’ financial condition and continued cooperation;
|
•
|
our ability to achieve the benefits of acquisitions or other investments within expected time frames or at all, or within expected cost projections;
|
•
|
the potential impact on us and our tenants, operators and borrowers from current and future litigation matters, including the possibility of larger than expected litigation costs, adverse results and related developments;
|
•
|
operational risks associated with third party management contracts, including the additional regulation and liabilities of our RIDEA lease structures;
|
•
|
the effect on us and our tenants and operators of legislation, executive orders and other legal requirements, including compliance with the Americans with Disabilities Act, fire, safety and health regulations, environmental laws, the Affordable Care Act, licensure, certification and inspection requirements, and laws addressing entitlement programs and related services, including Medicare and Medicaid, which may result in future reductions in reimbursements or fines for noncompliance;
|
•
|
changes in federal, state or local laws and regulations, including those affecting the healthcare industry that affect our costs of compliance or increase the costs, or otherwise affect the operations, of our tenants and operators;
|
•
|
our ability to foreclose on collateral securing our real estate-related loans;
|
•
|
volatility or uncertainty in the capital markets, the availability and cost of capital as impacted by interest rates, changes in our credit ratings, and the value of our common stock, and other conditions that may adversely impact our ability to fund our obligations or consummate transactions, or reduce the earnings from potential transactions;
|
•
|
changes in global, national and local economic and other conditions, including currency exchange rates;
|
•
|
our ability to manage our indebtedness level and changes in the terms of such indebtedness;
|
•
|
competition for skilled management and other key personnel;
|
•
|
the potential impact of uninsured or underinsured losses;
|
•
|
our reliance on information technology systems and the potential impact of system failures, disruptions or breaches; and
|
•
|
our ability to maintain our qualification as a real estate investment trust (“REIT”).
|
•
|
Executive Summary
|
•
|
2018
Transaction Overview
|
•
|
Dividends
|
•
|
Results of Operations
|
•
|
Liquidity and Capital Resources
|
•
|
Off-Balance Sheet Arrangements
|
•
|
Non-GAAP Financial Measures Reconciliations
|
•
|
Critical Accounting Policies
|
•
|
Recent Accounting Pronouncements
|
•
|
In January 2018, we sold the first of six agreed upon facilities to Brookdale Senior Living, Inc. (“Brookdale”) for $32 million. In April 2018, we sold the remaining five facilities to Brookdale for $243 million.
|
•
|
In March 2018, we completed the acquisition of Brookdale’s noncontrolling interest in RIDEA I for $63 million.
|
•
|
As of March 31, 2018, we had completed the transition of eight assets previously operated by Brookdale to other operators.
|
•
|
On May 1, 2018, we entered into definitive agreements with an institutional investor to create a joint venture (the “U.K. JV”) through which we will sell a 51% interest in all United Kingdom (“U.K.”) assets owned by us (the “U.K. Portfolio”) based on a total value of £394 million. We will retain a 49% noncontrolling interest in the joint venture. Upon closing the U.K. JV, we expect to deconsolidate the U.K. Portfolio and recognize a gain on deconsolidation.
|
•
|
In 2016, we provided a £105 million ($131 million at closing) bridge loan to Maria Mallaband Care Group Ltd. to fund the acquisition of a portfolio of seven care homes in the U.K. Under the bridge loan, we retained a call option to acquire those seven care homes at a future date for £105 million, subject to certain conditions being met. In March 2018, in conjunction with Maria Mallaband and HCP satisfying the conditions necessary to exercise our call option to acquire the seven care homes, we began consolidating the real estate. As a result, we derecognized the outstanding loan receivable and recognized a £29 million ($41 million) loss on consolidation for the difference between the carrying value of the loan receivable and the fair value of net assets and liabilities assumed, primarily real estate. See Notes 6 and 15 to the Consolidated Financial Statements for additional information.
|
•
|
In March 2018, we sold our Tandem Health Care mezzanine loan (“Tandem Mezzanine Loan”) to a third party for approximately $112 million, resulting in an impairment recovery, net of transaction costs and fees, of $3 million.
|
•
|
In April 2018, we sold a SHOP facility located in Texas for $23 million.
|
•
|
On April 6, 2018, we repaid $290 million outstanding under our revolving credit facility, primarily using proceeds from asset sales to Brookdale (see Brookdale Transactions Update above).
|
•
|
In March 2018, we acquired the rights to develop a new 214,000 square foot life science facility on our existing Hayden Research Campus in Lexington, Massachusetts for $21 million. The planned development, 75 Hayden, will be a four-story, purpose-built Class A life science facility and parking garage.
|
Declaration Date
|
|
Record Date
|
|
Amount
Per Share
|
|
Dividend
Payable Date
|
||
February 1
|
|
February 15
|
|
$
|
0.37
|
|
|
March 2
|
April 26
|
|
May 7
|
|
0.37
|
|
|
May 22
|
|
Three Months Ended March 31,
|
|
|
|||||||||
|
2018
|
|
|
2017
|
|
Change
|
||||||
Net income (loss) applicable to common shares
|
$
|
39,841
|
|
|
|
$
|
460,375
|
|
|
$
|
(420,534
|
)
|
FFO
|
219,434
|
|
|
|
288,249
|
|
|
(68,815
|
)
|
|||
FFO as adjusted
|
227,352
|
|
|
|
240,172
|
|
|
(12,820
|
)
|
|||
FAD
|
201,736
|
|
|
|
218,555
|
|
|
(16,819
|
)
|
•
|
a reduction in net gain on sales of real estate during the first quarter of 2018 compared to the first quarter of
2017
;
|
•
|
a loss on consolidation of seven care homes in the U.K. during the first quarter of 2018;
|
•
|
a gain on sale of our Four Seasons senior notes (“Four Seasons Notes”) during the first quarter of
2017
, which was not replicated during the first quarter of 2018;
|
•
|
a reduction in NOI, primarily as a result of the sale of 64 senior housing triple-net assets during the first quarter of
2017
;
|
•
|
a reduction in resident fees and services, partially offset by a reduction in operating expenses, due to the partial sale and deconsolidation of RIDEA II during the first quarter of 2017;
|
•
|
an increase in severance and related charges during the first quarter of 2018 related to the departure of our former Executive Chairman; and
|
•
|
a reduction in interest income due to the: (i) sale of our Tandem Mezzanine Loan in March 2018 and (ii) payoff of our HC-One Facility in June 2017.
|
•
|
increased NOI from our 2017 acquisitions, annual rent escalations and developments placed in service, primarily in our life science and medical office segments; and
|
•
|
a reduction in interest expense as a result of debt repayments primarily in the third quarter of 2017.
|
•
|
an increase in severance and related charges; and
|
•
|
a gain on sale of our Four Seasons Notes during the first quarter of
2017
.
|
|
SPP
|
|
Total Portfolio
|
||||||||||||||||||||
|
Three Months Ended March 31,
|
|
Three Months Ended March 31,
|
||||||||||||||||||||
|
2018
|
|
2017
|
|
Change
|
|
2018
|
|
2017
|
|
Change
|
||||||||||||
Rental revenues
(1)
|
$
|
73,217
|
|
|
$
|
70,222
|
|
|
$
|
2,995
|
|
|
$
|
74,289
|
|
|
$
|
100,034
|
|
|
$
|
(25,745
|
)
|
Operating expenses
|
(146
|
)
|
|
(128
|
)
|
|
(18
|
)
|
|
(1,045
|
)
|
|
(1,111
|
)
|
|
66
|
|
||||||
NOI
|
73,071
|
|
|
70,094
|
|
|
2,977
|
|
|
73,244
|
|
|
98,923
|
|
|
(25,679
|
)
|
||||||
Adjustments to NOI
|
(1,849
|
)
|
|
794
|
|
|
(2,643
|
)
|
|
(1,865
|
)
|
|
(1,839
|
)
|
|
(26
|
)
|
||||||
Adjusted NOI
|
$
|
71,222
|
|
|
$
|
70,888
|
|
|
$
|
334
|
|
|
71,379
|
|
|
97,084
|
|
|
(25,705
|
)
|
|||
Non-SPP adjusted NOI
|
|
|
|
|
|
|
|
|
|
(157
|
)
|
|
(26,196
|
)
|
|
26,039
|
|
||||||
SPP adjusted NOI
|
|
|
|
|
|
|
|
|
|
$
|
71,222
|
|
|
$
|
70,888
|
|
|
$
|
334
|
|
|||
Adjusted NOI % change
|
|
|
|
|
|
|
0.5
|
%
|
|
|
|
|
|
|
|
|
|
||||||
Property count
(2)
|
179
|
|
|
179
|
|
|
|
|
|
181
|
|
|
209
|
|
|
|
|
||||||
Average capacity (units)
(3)
|
18,123
|
|
|
18,136
|
|
|
|
|
|
18,331
|
|
|
26,435
|
|
|
|
|
||||||
Average annual rent per unit
|
$
|
15,752
|
|
|
$
|
15,663
|
|
|
|
|
|
$
|
15,803
|
|
|
$
|
14,858
|
|
|
|
|
(1)
|
Represents rental and related revenues and income from DFLs.
|
(2)
|
From our
2017
presentation of SPP, we removed four senior housing properties from SPP that were classified as held for sale and 24 senior housing properties that we transitioned to SHOP.
|
(3)
|
Represents average capacity as reported by the respective tenants or operators for the 12-month period and a quarter in arrears from the periods presented.
|
•
|
senior housing triple-net facilities sold during 2017; and
|
•
|
the transfer of 24 senior housing triple-net facilities to our SHOP segment during 2017.
|
|
SPP
|
|
Total Portfolio
|
||||||||||||||||||||
|
Three Months Ended March 31,
|
|
Three Months Ended March 31,
|
||||||||||||||||||||
|
2018
|
|
2017
|
|
Change
|
|
2018
|
|
2017
|
|
Change
|
||||||||||||
Rental revenues
(1)
|
$
|
108,944
|
|
|
$
|
108,782
|
|
|
$
|
162
|
|
|
$
|
144,670
|
|
|
$
|
140,228
|
|
|
$
|
4,442
|
|
Operating expenses
|
(74,291
|
)
|
|
(71,067
|
)
|
|
(3,224
|
)
|
|
(101,746
|
)
|
|
(94,539
|
)
|
|
(7,207
|
)
|
||||||
NOI
|
34,653
|
|
|
37,715
|
|
|
(3,062
|
)
|
|
42,924
|
|
|
45,689
|
|
|
(2,765
|
)
|
||||||
Adjustments to NOI
|
393
|
|
|
(291
|
)
|
|
684
|
|
|
(1,607
|
)
|
|
(310
|
)
|
|
(1,297
|
)
|
||||||
Adjusted NOI
|
$
|
35,046
|
|
|
$
|
37,424
|
|
|
$
|
(2,378
|
)
|
|
41,317
|
|
|
45,379
|
|
|
(4,062
|
)
|
|||
Non-SPP adjusted NOI
|
|
|
|
|
|
|
|
|
|
(6,271
|
)
|
|
(7,955
|
)
|
|
1,684
|
|
||||||
SPP adjusted NOI
|
|
|
|
|
|
|
|
|
|
$
|
35,046
|
|
|
$
|
37,424
|
|
|
$
|
(2,378
|
)
|
|||
Adjusted NOI % change
|
|
|
|
|
|
|
(6.4
|
)%
|
|
|
|
|
|
|
|
|
|
||||||
Property count
(2)
|
69
|
|
|
69
|
|
|
|
|
|
100
|
|
|
81
|
|
|
|
|
||||||
Average capacity (units)
(3)
|
10,317
|
|
|
10,333
|
|
|
|
|
|
13,597
|
|
|
13,091
|
|
|
|
|
||||||
Average annual rent per unit
|
$
|
48,559
|
|
|
$
|
47,003
|
|
|
|
|
|
$
|
49,103
|
|
|
$
|
48,576
|
|
|
|
|
(1)
|
Represents resident fees and services.
|
(2)
|
From our
2017
presentation of SPP, we removed two SHOP properties from SPP that were sold and three SHOP properties were classified as held for sale.
|
(3)
|
Represents average capacity as reported by the respective tenants or operators for the 12-month period and a quarter in arrears from the periods presented.
|
•
|
occupancy declines and higher labor costs; partially offset by
|
•
|
increased rates for resident fees.
|
•
|
decreased non-SPP income from our partial sale of RIDEA II in the first quarter of 2017; partially offset by
|
•
|
non-SPP income for 24 senior housing triple-net assets transferred to SHOP during 2017.
|
|
SPP
|
|
Total Portfolio
|
||||||||||||||||||||
|
Three Months Ended March 31,
|
|
Three Months Ended March 31,
|
||||||||||||||||||||
|
2018
|
|
2017
|
|
Change
|
|
2018
|
|
2017
|
|
Change
|
||||||||||||
Rental revenues
(1)
|
$
|
75,584
|
|
|
$
|
73,894
|
|
|
$
|
1,690
|
|
|
$
|
99,622
|
|
|
$
|
85,321
|
|
|
$
|
14,301
|
|
Operating expenses
|
(15,428
|
)
|
|
(14,424
|
)
|
|
(1,004
|
)
|
|
(21,809
|
)
|
|
(17,319
|
)
|
|
(4,490
|
)
|
||||||
NOI
|
60,156
|
|
|
59,470
|
|
|
686
|
|
|
77,813
|
|
|
68,002
|
|
|
9,811
|
|
||||||
Adjustments to NOI
|
(64
|
)
|
|
379
|
|
|
(443
|
)
|
|
(3,751
|
)
|
|
(305
|
)
|
|
(3,446
|
)
|
||||||
Adjusted NOI
|
$
|
60,092
|
|
|
$
|
59,849
|
|
|
$
|
243
|
|
|
74,062
|
|
|
67,697
|
|
|
6,365
|
|
|||
Non-SPP adjusted NOI
|
|
|
|
|
|
|
|
|
|
(13,970
|
)
|
|
(7,848
|
)
|
|
(6,122
|
)
|
||||||
SPP adjusted NOI
|
|
|
|
|
|
|
|
|
|
$
|
60,092
|
|
|
$
|
59,849
|
|
|
$
|
243
|
|
|||
Adjusted NOI % change
|
|
|
|
|
|
|
0.4
|
%
|
|
|
|
|
|
|
|
|
|
||||||
Property count
(2)
|
108
|
|
|
108
|
|
|
|
|
|
131
|
|
|
124
|
|
|
|
|
||||||
Average occupancy
|
94.6
|
%
|
|
95.9
|
%
|
|
|
|
|
93.7
|
%
|
|
96.2
|
%
|
|
|
|
||||||
Average occupied square feet
|
6,010
|
|
|
6,091
|
|
|
|
|
|
7,289
|
|
|
6,682
|
|
|
|
|
||||||
Average annual total revenues per occupied square foot
|
$
|
50
|
|
|
$
|
49
|
|
|
|
|
|
$
|
53
|
|
|
$
|
51
|
|
|
|
|
||
Average annual base rent per occupied square foot
|
$
|
41
|
|
|
$
|
40
|
|
|
|
|
|
$
|
43
|
|
|
$
|
42
|
|
|
|
|
(1)
|
Represents rental and related revenues and tenant recoveries.
|
(2)
|
From our
2017
presentation of SPP, we removed a life science facility that was sold and a life science facility that was placed in redevelopment. Our
2017
total portfolio property count has been adjusted to include eight properties in development as of
March 31, 2017
.
|
•
|
increased income from: (i) increased occupancy in portions of a development placed into operations in 2017 and 2018 and (ii) acquisitions in 2017; partially offset by
|
•
|
decreased income from the placement of life science facilities into redevelopment in 2017 and 2018 and the sale of life science facilities in 2017.
|
|
SPP
|
|
Total Portfolio
|
||||||||||||||||||||
|
Three Months Ended March 31,
|
|
Three Months Ended March 31,
|
||||||||||||||||||||
|
2018
|
|
2017
|
|
Change
|
|
2018
|
|
2017
|
|
Change
|
||||||||||||
Rental revenues
(1)
|
$
|
104,626
|
|
|
$
|
103,240
|
|
|
$
|
1,386
|
|
|
$
|
123,935
|
|
|
$
|
118,371
|
|
|
$
|
5,564
|
|
Operating expenses
|
(37,845
|
)
|
|
(37,202
|
)
|
|
(643
|
)
|
|
(46,696
|
)
|
|
(44,864
|
)
|
|
(1,832
|
)
|
||||||
NOI
|
66,781
|
|
|
66,038
|
|
|
743
|
|
|
77,239
|
|
|
73,507
|
|
|
3,732
|
|
||||||
Adjustments to NOI
|
(393
|
)
|
|
(678
|
)
|
|
285
|
|
|
(1,071
|
)
|
|
(961
|
)
|
|
(110
|
)
|
||||||
Adjusted NOI
|
$
|
66,388
|
|
|
$
|
65,360
|
|
|
$
|
1,028
|
|
|
76,168
|
|
|
72,546
|
|
|
3,622
|
|
|||
Non-SPP adjusted NOI
|
|
|
|
|
|
|
|
|
|
(9,780
|
)
|
|
(7,186
|
)
|
|
(2,594
|
)
|
||||||
SPP adjusted NOI
|
|
|
|
|
|
|
|
|
|
$
|
66,388
|
|
|
$
|
65,360
|
|
|
$
|
1,028
|
|
|||
Adjusted NOI % change
|
|
|
|
|
|
|
1.6
|
%
|
|
|
|
|
|
|
|
|
|
||||||
Property count
(2)
|
225
|
|
|
225
|
|
|
|
|
|
254
|
|
|
242
|
|
|
|
|
||||||
Average occupancy
|
92.1
|
%
|
|
92.5
|
%
|
|
|
|
|
91.9
|
%
|
|
91.9
|
%
|
|
|
|
||||||
Average occupied square feet
|
15,007
|
|
|
15,174
|
|
|
|
|
|
16,969
|
|
|
16,658
|
|
|
|
|
||||||
Average annual total revenues per occupied square foot
|
$
|
28
|
|
|
$
|
27
|
|
|
|
|
|
$
|
29
|
|
|
$
|
28
|
|
|
|
|
||
Average annual base rent per occupied square foot
|
$
|
23
|
|
|
$
|
23
|
|
|
|
|
|
$
|
24
|
|
|
$
|
24
|
|
|
|
|
(1)
|
Represents rental and related revenues and tenant recoveries.
|
(2)
|
From our
2017
presentation of SPP, we removed four MOBs that were sold and four MOBs that were placed into redevelopment. Our
2017
property count has been adjusted to include four properties in development as of
March 31, 2017
.
|
•
|
increased income from our 2017 acquisitions; and
|
•
|
increased occupancy in former redevelopment and development properties that have been placed into operations; partially offset by
|
•
|
decreased income from the sale of four MOBs during 2017.
|
|
Three Months Ended March 31,
|
||||||||||
|
2018
|
|
2017
|
|
Change
|
||||||
Interest income
|
$
|
6,365
|
|
|
$
|
18,331
|
|
|
$
|
(11,966
|
)
|
Interest expense
|
75,102
|
|
|
86,718
|
|
|
(11,616
|
)
|
|||
Depreciation and amortization
|
143,250
|
|
|
136,554
|
|
|
6,696
|
|
|||
General and administrative
|
29,175
|
|
|
22,478
|
|
|
6,697
|
|
|||
Transaction costs
|
2,195
|
|
|
1,057
|
|
|
1,138
|
|
|||
Gain (loss) on sales of real estate, net
|
20,815
|
|
|
317,258
|
|
|
(296,443
|
)
|
|||
Other income (expense), net
|
(40,407
|
)
|
|
51,208
|
|
|
(91,615
|
)
|
|||
Income tax benefit (expense)
|
5,336
|
|
|
6,162
|
|
|
(826
|
)
|
|||
Equity income (loss) from unconsolidated joint ventures
|
570
|
|
|
3,269
|
|
|
(2,699
|
)
|
|||
Noncontrolling interests’ share in earnings
|
(3,005
|
)
|
|
(3,032
|
)
|
|
27
|
|
•
|
fund capital expenditures, including tenant improvements and leasing costs; and
|
•
|
fund future acquisition, transactional and development activities.
|
•
|
sale or exchange of ownership interests in properties;
|
•
|
draws on our credit facilities;
|
•
|
issuance of additional debt, including unsecured notes and mortgage debt; and/or
|
•
|
issuance of common or preferred stock.
|
|
Three Months Ended March 31,
|
||||||||||
|
2018
|
|
2017
|
|
Change
|
||||||
Net cash provided by (used in) operating activities
|
$
|
196,164
|
|
|
$
|
193,129
|
|
|
$
|
3,035
|
|
Net cash provided by (used in) investing activities
|
10,728
|
|
|
1,733,763
|
|
|
(1,723,035
|
)
|
|||
Net cash provided by (used in) financing activities
|
(171,238
|
)
|
|
(1,238,969
|
)
|
|
1,067,731
|
|
•
|
received net proceeds of $163 million primarily from the sale of our Tandem Mezzanine Loan and real estate; and
|
•
|
made investments of $159 million primarily for the development of real estate.
|
•
|
received net proceeds of $1.7 billion from the sale of real estate, including the sale and recapitalization of RIDEA II;
|
•
|
received net proceeds of $185 million primarily from the sale of our Four Seasons investments and DFL repayment; and
|
•
|
made investments of $121 million primarily for the development of real estate.
|
•
|
made net borrowings of $70 million under our bank line of credit;
|
•
|
paid $63 million to purchase Brookdale’s noncontrolling interest in RIDEA I; and
|
•
|
paid cash dividends on common stock of $174 million.
|
•
|
made net repayments of $1.1 billion under our bank line of credit, term loans and mortgage debt; and
|
•
|
paid dividends on common stock of $174 million.
|
|
Three Months Ended
March 31, |
||||||
|
2018
|
|
2017
|
||||
Net income (loss) applicable to common shares
|
$
|
39,841
|
|
|
$
|
460,375
|
|
Real estate related depreciation and amortization
|
143,250
|
|
|
136,554
|
|
||
Real estate related depreciation and amortization on unconsolidated joint ventures
|
17,388
|
|
|
15,039
|
|
||
Real estate related depreciation and amortization on noncontrolling interests and other
|
(2,543
|
)
|
|
(3,972
|
)
|
||
Other depreciation and amortization
|
1,296
|
|
|
3,010
|
|
||
Loss (gain) on sales of real estate, net
|
(20,815
|
)
|
|
(317,258
|
)
|
||
Loss (gain) upon consolidation of real estate, net
(1)
|
41,017
|
|
|
—
|
|
||
Taxes associated with real estate dispositions
(2)
|
—
|
|
|
(5,499
|
)
|
||
FFO applicable to common shares
|
219,434
|
|
|
288,249
|
|
||
Distributions on dilutive convertible units
|
—
|
|
|
2,803
|
|
||
Diluted FFO applicable to common shares
|
$
|
219,434
|
|
|
$
|
291,052
|
|
|
|
|
|
||||
Weighted average shares outstanding - diluted FFO
|
469,695
|
|
|
475,173
|
|
||
|
|
|
|
||||
Impact of adjustments to FFO:
|
|
|
|
|
|
||
Transaction-related items
|
$
|
1,942
|
|
|
$
|
1,057
|
|
Other impairments (recoveries), net
(3)
|
(3,298
|
)
|
|
(50,895
|
)
|
||
Severance and related charges
(4)
|
8,738
|
|
|
—
|
|
||
Litigation costs
|
406
|
|
|
1,838
|
|
||
Foreign currency remeasurement losses (gains)
|
130
|
|
|
(77
|
)
|
||
Total adjustments
|
$
|
7,918
|
|
|
$
|
(48,077
|
)
|
|
|
|
|
||||
FFO as adjusted applicable to common shares
|
$
|
227,352
|
|
|
$
|
240,172
|
|
Distributions on dilutive convertible units and other
|
1,711
|
|
|
2,877
|
|
||
Diluted FFO as adjusted applicable to common shares
|
$
|
229,063
|
|
|
$
|
243,049
|
|
|
|
|
|
||||
Weighted average shares outstanding - diluted FFO as adjusted
|
474,363
|
|
|
475,173
|
|
|
Three Months Ended
March 31, |
||||||
|
2018
|
|
2017
|
||||
FFO as adjusted applicable to common shares
|
$
|
227,352
|
|
|
$
|
240,172
|
|
Amortization of deferred compensation
(5)
|
3,420
|
|
|
3,765
|
|
||
Amortization of deferred financing costs
|
3,336
|
|
|
3,858
|
|
||
Straight-line rents
|
(10,686
|
)
|
|
(7,396
|
)
|
||
FAD capital expenditures
(6)
|
(19,118
|
)
|
|
(22,077
|
)
|
||
Lease restructure payments
|
299
|
|
|
540
|
|
||
CCRC entrance fees
(7)
|
3,027
|
|
|
3,649
|
|
||
Deferred income taxes
|
(2,140
|
)
|
|
(2,374
|
)
|
||
Other FAD adjustments
|
(3,754
|
)
|
|
(1,582
|
)
|
||
FAD applicable to common shares
|
201,736
|
|
|
218,555
|
|
||
Distributions on dilutive convertible units
|
—
|
|
|
2,803
|
|
||
Diluted FAD applicable to common shares
|
$
|
201,736
|
|
|
$
|
221,358
|
|
|
Three Months Ended
March 31, |
||||||
|
2018
|
|
2017
|
||||
Diluted earnings per common share
|
$
|
0.08
|
|
|
$
|
0.97
|
|
Depreciation and amortization
|
0.34
|
|
|
0.32
|
|
||
Loss (gain) on sales of real estate, net
|
(0.04
|
)
|
|
(0.67
|
)
|
||
Loss (gain) upon consolidation of real estate, net
(1)
|
0.09
|
|
|
—
|
|
||
Taxes associated with real estate dispositions
(2)
|
—
|
|
|
(0.01
|
)
|
||
Diluted FFO per common share
|
$
|
0.47
|
|
|
$
|
0.61
|
|
Other impairments (recoveries), net
(3)
|
(0.01
|
)
|
|
(0.10
|
)
|
||
Severance and related charges
(4)
|
0.02
|
|
|
—
|
|
||
Diluted FFO as adjusted per common share
|
$
|
0.48
|
|
|
$
|
0.51
|
|
(1)
|
For the three months ended March 31, 2018, represents the loss on consolidation of seven U.K
. care homes.
|
(2)
|
For the three months ended March 31, 2017, represents income tax benefit associated with the disposition of real estate assets in our RIDEA II transaction.
|
(3)
|
For the three months ended March 31, 2018, represents the impairment recovery upon sale of our Tandem Health Care mezzanine loan ("Tandem Mezzanine Loan") in March 2018. For the three months ended March 31, 2017, represents the impairment recovery upon the sale of our Four Seasons Health Care senior notes in the first quarter of 2017.
|
(4)
|
For the three months ended March 31, 2018, relates to the departure of our former Executive Chairman, including $6 million of cash severance and $3 million of equity award vestings.
|
(5)
|
Excludes $3 million related to the acceleration of deferred compensation for restricted stock units that vested upon the departure of our former Executive Chairman, which is included in severance and related charges for the three months ended March 31, 2018.
|
(6)
|
Excludes our share of recurring capital expenditures, leasing costs, and tenant and capital improvements from unconsolidated joint ventures (reported in "Other FAD adjustments").
|
(7)
|
Represents our 49% share of non-refundable entrance fees as the fees are collected by our CCRC JV, net of reserves and CCRC JV entrance fee amortization.
|
Period Covered
|
|
Total Number
Of Shares
Purchased
(1)
|
|
Average
Price
Paid Per
Share
|
|
Total Number Of Shares
(Or Units) Purchased As
Part Of Publicly
Announced Plans Or
Programs
|
|
Maximum Number (Or
Approximate Dollar Value)
Of Shares (Or Units) That
May Yet Be Purchased
Under The Plans Or
Programs
|
|||||
January 1-31, 2018
|
|
44
|
|
|
$
|
23.33
|
|
|
—
|
|
|
—
|
|
February 1-28, 2018
|
|
83,997
|
|
|
23.30
|
|
|
—
|
|
|
—
|
|
|
March 1-31, 2018
|
|
8,572
|
|
|
21.64
|
|
|
—
|
|
|
—
|
|
|
Total
|
|
92,613
|
|
|
25.41
|
|
|
—
|
|
|
—
|
|
(1)
|
Represents shares of our common stock withheld under our equity incentive plans to offset tax withholding obligations that occur upon vesting of restricted shares. The value of the shares withheld is based on the closing price of our common stock on the last trading day prior to the date the relevant transaction occurs.
|
Date: May 3, 2018
|
HCP, Inc.
|
|
|
|
(Registrant)
|
|
|
|
/s/ THOMAS M. HERZOG
|
|
Thomas M. Herzog
|
|
President and Chief Executive Officer
|
|
(Principal Executive Officer)
|
|
|
|
/s/ PETER A. SCOTT
|
|
Peter A. Scott
|
|
Executive Vice President and
|
|
Chief Financial Officer
|
|
(Principal Financial Officer)
|
|
|
|
/s/ SHAWN G. JOHNSTON
|
|
Shawn G. Johnston
|
|
Senior Vice President and
|
|
Chief Accounting Officer
|
|
(Principal Accounting Officer)
|
1.
|
Section 5 of the Plan is hereby amended to add a Section 5.9 to read in its entirety as follows:
|
5.9.1
|
Any award granted hereunder shall provide for a time-based or performance-based vesting schedule, as applicable, of at least one (1) year following the date of grant.
|
5.9.2
|
Notwithstanding anything set forth in Section 5.9.1 to the contrary, awards representing a maximum of five percent (5%) of the Share Limit may be granted hereunder without any minimum vesting condition.
|
2.
|
The first sentence of Section 5.2 of the Plan is hereby deleted in its entirety and replaced with the following:
|
3.
|
Section 8.8.3(b) of the Plan is hereby deleted in its entirety.
|
4.
|
Except as amended by this Amendment, the Plan shall remain in full force and effect in accordance with its terms.
|
5.
|
This Amendment shall be governed by, and construed in accordance with the laws of the State of Maryland.
|
•
|
The following constituents:
|
o
|
[__________]; and
|
•
|
Any other constituent that is subject during the Performance Period to a merger, sale or spin-off of all or substantially all of its assets, or other business combination that would artificially distort its TSR, provided that if the constituent is the acquirer
|
4
|
|
|
Date: May 3, 2018
|
/s/ THOMAS M. HERZOG
|
|
|
Thomas M. Herzog
|
|
|
President and Chief Executive Officer
|
|
|
(Principal Executive Officer)
|
4
|
|
|
Date: May 3, 2018
|
/s/ PETER A. SCOTT
|
|
|
Peter A. Scott
|
|
|
Executive Vice President and
|
|
|
Chief Financial Officer
|
|
|
(Principal Financial Officer)
|
|
|
Date: May 3, 2018
|
/s/ THOMAS M. HERZOG
|
|
Thomas M. Herzog
|
|
President and Chief Executive Officer
|
|
(Principal Executive Officer)
|
|
|
Date: May 3, 2018
|
/s/ PETER A. SCOTT
|
|
Peter A. Scott
|
|
Executive Vice President and
|
|
Chief Financial Officer
|
|
(Principal Financial Officer)
|